Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0356
Trial ID NCT03056339
Disease Acute Monocytic Leukemia | B-Lymphoid Malignancy | Chronic Lymphocytic Leukemia | Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-NK cell
Treatment CD19 CAR-NK cells
Generation2nd
PhasePhase1|Phase2
Recruitment statusCompleted
TitleUmbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Year2017
CountryUnited States
Company sponsorM.D. Anderson Cancer Center
Other ID(s)2016-0641|NCI-2018-01221

Clinical Result

Cohort1: dose level 1
Administration route intravenous infusion
Dosage 1E5 cells/kg
Pts 3
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 2/3(CR); 0/3(PR); 0/3(SD); 1/3(PD)
Adverse reactions 4/3(Grade ≥3 Toxicities)
Cohort2: dose level 2
Administration route intravenous infusion
Dosage 1E6 cells/kg
Pts 6
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 3/6(CR); 0/6(PR); 0/6(SD); 1/6(PD)
Adverse reactions 1/6(Grade ≥3 Toxicities)
Cohort3: dose level 3
Administration route intravenous infusion
Dosage 1E7 cells/kg
Pts 23
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 3/23(CR); 5/23(PR); 2/23(SD); 6/23(PD)
Adverse reactions 22/23(Grade ≥3 Toxicities)
Cohort4: dose level 4
Administration route intravenous infusion
Dosage 8E8 cells
Pts 17
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 5/17(CR); 3/17(PR); 5/17(SD); 2/17(PD)
Adverse reactions 1/17(Grade ≥ 3 Toxicities)

Relationship Graph

Overview of Knowledge Graph